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ABSTRACT
Chronic graft-versus-host disease (cGVHD) remains a problematic complication of allogeneic hematopoietic stem
cell transplantation. Laboratory parameters correlated with cGVHD have not been fully defined, although changes
in CD4/CD8 ratios occur and a decrease in CD4 central memory T cells has been noted. Extracorporeal
photopheresis (ECP) is an effective therapy for steroid-refractory cGVHD. We have noted changes in lymphocyte
subsets after ECP. CD4 and CD8 T-cell central and effector memory populations were enumerated by flow
cytometry in a cohort of 37 patients postallogeneic transplantation with symptomatic cGVHD. Of the patients with
symptomatic cGVHD, 7 were treated with ECP over 6 months and prospectively assessed for changes in lympho-
cyte subsets. There was a highly significant correlation of an increase in CD8 central memory cells and a
concomitant decrease in CD4 central memory cells in patients with symptomatic cGVHD. These changes were
not detected in patients without cGVHD posttransplantation. In all, 7 patients with cGVHD followed up prospec-
tively during ECP treatment showed a statistically significant normalization of the pattern of CD4 and a trend
toward normalization of CD8 central memory T cells coincident with improvement of cGVHD. These data
indicate a high correlation between disturbances in the balance of central and effector memory populations and
cGVHD suggesting use in following up responses to therapy. The normalization of central and effector memory
populations in response to ECP coincident with clinical improvement of cGVHD support a correlation between
these laboratory parameters and cGVHD. Further studies are needed to demonstrate whether laboratory mea-
surements of the magnitude of changes in central and effector memory populations are useful prognostically or can
be used to guide response to therapy. The contrasting change in central memory cells (CD8 increased versus
CD4 decreased) in cGVHDprovide support for recent reports suggesting unique differences in the differentiation
pathways for CD8 versus CD4 T cells.
© 2006 American Society for Blood and Marrow Transplantation
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Abnormal Central/Effector Memory T Cell Ratios
BNTRODUCTION
After allogeneic stem cell transplantation, chronic
raft-versus-host disease (cGVHD) is the most com-
on and life-threatening delayed transplantation-re-
ated complication [1]. Donor-derived, alloreactive T
ells play an important role in the pathogenesis of
GVHD, but their mechanism of action is uncertain.
he incidence of cGVHD of 30% to 50% is increas-
ng because of an increase in allogeneic stem cell
ransplantations for older patients, HLA antigen–mis-
atched transplants, peripheral blood stem cell trans-
lantations, and donor lymphocyte infusions for re-
apsed disease or unstable mixed chimerism [2,3].
Extracorporeal photopheresis (ECP) is an effec-
ive therapy for cGVHD in patients who are unre-
ponsive to ﬁrst-line treatment with corticosteroids
nd calcineurin inhibitors [4-7]. Lymphocytes exposed
o 8-methylpsoralen and UVA light undergo apopto-
is [8]; however, only 2% to 5% of the total circulating
ononuclear pool is exposed to UVA with each treat-
ent. Thus, ECP likely reduces manifestations of
raft-versus-host diseases (GVHD) by changing the
alance of alloimmune activity by mechanisms other
han simply the removal of alloreactive lymphoid
lones. Recently, it has been reported that ECP results
n a normalization of the inverted CD4/CD8 ratio,
ncreased CD3CD56 natural killer (NK) cells, de-
reased CD80CD123 circulating dendritic cells,
ith a shift in dendritic polarization from a predom-
nantly dendritic cell 1 to a dendritic cell 2 pattern
9,10]. Concurrently there is a shift in CD4 T-cell
olarity from a predominantly TH1 pattern to a TH2
ytokine proﬁle [10]. However, the precise mecha-
ism of action of ECP has yet to be deﬁned and a
ecent report from a study of 28 patients with
GVHD treated with ECP found no laboratory
arameter that predicted a favorable response to
CP [7].
Human peripheral blood CD4 and CD8T cells
an be grouped into functionally distinct subpopula-
ions by the pattern of expression of chemokine re-
eptor, CCR7. CD4 T cells consist of one naive
CD45RACCR7) and twomemory subsets,CD45RA
CR7 (central memory) and CD45RACCR7 (ef-
ector memory). Within CD8 T cells, the same 3 sub-
ets have been identiﬁed, with a fourth CD45RA
CR7CD8 T-cell (effector memory) subset [11]. In
ubsets of memory T cells it has been noted that the
dhesion molecule, CD62L (L-selectin) is usually ex-
ressed on the same cells that express CCR7 [11].
oth molecules appear pivotal for migration into sec-
ndary lymphoid organs [12,13].
upported by Japan Society for the Promotion of Science Research Fellow-
hips for Japanese Biomedical and Behavioral Researchers at Nationalrnstitutes of Health (Dr Yamashita) and Therakos Inc.
B&MTWe have recently reported that severe cGVHD is
haracterized by a preponderance of CD4 effector
emory T cells relative to CD4 central memory T
ells, compared with healthy individuals or patients
ith stem cell transplantation without cGVHD, in
hom central memory CD4T cells are predominant
n the peripheral blood [14]. In this study, we further
xamined whether clinical amelioration of cGVHD in
esponse to ECP normalizes the abnormal patterns of
-cell memory subpopulations. We also extend our
revious observations on memory CD4 T cells in
VHD to the CD8 T-cell memory compartments.
n contrast to CD4 T cells where there is a signiﬁ-
ant deﬁciency of central memory cells with preser-
ation of effector memory populations associated with
GVHD, the CD8 T-cell compartment demon-
trates a marked increase in the proportion of central
emory cells with little change in the numbers of
ffector memory cells. There is also a modest decrease
n the RA effector memory population unique to
D8 cells associated with cGVHD. We report here
or the ﬁrst time that the unique changes of both
D4 and CD8 central memory cells associated
ith cGVHD normalize after ECP treatment. These
ndings have implications for modeling memory T-cell
ifferentiation pathways and may provide a marker to
onitor response to ECP.
ETHODS
atients and ECP Treatment
All patients studied had been enrolled onto Na-
ional Institutes of Health (NIH) allogeneic stem cell
ransplantation protocols, conditioned with either my-
loablative or nonmyeloablative regimens, and were un-
ergoing transplantation from 6/6 or 5/6 HLA antigen–
atched related donors. All patients were enrolled on
ne of a number of NIH institutional review board–
pproved protocols and all signed informed consent
llowing study of blood cell phenotypes. A single
lood sample was obtained from 37 patients with
GVHD. Patients had at least one unequivocal man-
festation of cGVHD at the time of evaluation affect-
ng skin, mouth, eyes, lungs, joints, fascia, or gastro-
ntestinal system that required corticosteroids for
ontrol of symptoms. Most patients also received a
alcineurin inhibitor, and some were being treated
ith additional medications. From this group, 7 pa-
ients were referred to and enrolled in a protocol to
tudy the effect of ECP and allowing observation of
ongitudinal changes in lymphocyte subsets in re-
ponse to this therapy. All 7 patients referred for ECP
herapy had active and extensive cGVHD refractory to
orticosteroid and/or calcineurin inhibitor therapy.
ore detailed characteristics of these 7 patients en-olled in the ECP protocol are shown in Table 1. The
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2lood samples from normal healthy control subjects
nd from patients with non-GVHD autoimmune dis-
rders on high-dose steroids were also obtained under
nformed consent under institutional review board–
pproved protocol
CP Treatment Protocol
ECP treatment was administered by trained nurs-
ng staff under medical supervision using the UVAR
TS system consisting of the extracorporeal blood
ell separation and irradiation device, associated at-
achments, and UVADEX (methoxsalen), all manu-
actured by Therakos Inc, Exton, Pa, and used accord-
ng to manufacturer’s instructions. Therakos Inc
rovided some support for the conduct of this study in
he context of a cooperative research and development
greement with the National Institute of Allergy and
nfectious Diseases. ECP treatment was administered
n the Apheresis Section of the Division of Transfu-
ion Medicine, Warren H. Magnuson Clinical Center,
IH. Each procedure typically consisted of 5 to 6
ycles of collection and separation of buffy coat leu-
ocytes (consisting of about 2%-5% of circulating
eukocytes), followed by exposure of the pooled leu-
ocytes to 8-methylpsoralen and UVA, and return to
he patient. Each patient received two treatments per
eek for the ﬁrst 3 months, followed by two treat-
ents every other week for up to an additional 3
onths.
Response to ECP was evaluated by several meth-
ds. The primary clinical objective of the ECP trial
as to reduce the level of corticosteroid dosage re-
uired to control pain and/or maintain performance
f activities of daily living. All 7 patients achieved a
reater than 30% reduction in steroid dose while
howing improvement of one or more performance
arameters.
ell Preparation and Flow Cytometry
Peripheral blood mononuclear cells were isolated
able 1. Extracorporeal Photopheresis Patient Characteristics
Patient
Age
(y), Sex Disease
Duration
of cGVHD
Initiation of
ECP after SC
1 19/F ALL 2 y 2.5 y
2 37/F NHL 2 y 3 y
3 43/M NHL 10 y 10 y
4 32/F CML 9 mo 18 mo
5 19/M HD 4 mo 8 mo
6 40/M NHL 5 mo 11 mo
7 53/F AA 2 mo 5 mo
A indicates aplastic anemia; ALL, acute lymphoblastic leukemia;
leukemia; CSA, cyclosporin A; ECP, extracorporeal photopheres
mycophenolate mofetil; NHL, non-Hodgkin’s lymphoma; Predrom anticoagulated venous blood using lymphocyte u
4eparation medium according to manufacturer’s in-
tructions (ICN Biomedicals Inc, Aurora, Ohio).
reshly isolated peripheral blood mononuclear cells
ere analyzed using a ﬂow cytometer (FACSort,
D Biosciences, San Jose, Calif). CD4 cells were
tained with ﬂuorescein isothiocyanate–conjugated
ntihuman CD4 monoclonal antibody (mAb), phycoer-
thrin-conjugated antihuman CD45RO mAb, allo-
hycocyanin-conjugated antihuman CD62L mAb,
nd biotinylated antihuman CCR7 mAb in combi-
ation with cychrome-conjugated streptavidin (BD
iosciences) following the manufacturer’s protocol.
D8 cells were stained with ﬂuorescein isothio-
yanate–conjugated antihuman CD8 mAb, phyco-
rythrin-conjugated antihuman CCR4 mAb, allophy-
ocyanin-conjugated antihuman CD45RA mAb, and
iotinylated antihuman CCR7 mAb in combination
ith cychrome-conjugated streptavidin (BD Bio-
ciences) following the manufacturer’s protocol. Data
cquisition and postacquisition analysis was performed
ith software (CellQuest, BD Biosciences).
tatistical Analysis
The data are shown as means SEM. Two-group
omparison was done on the analysis of variance and
tudents t test. For the analysis of 2-dimensional dot
lots, logarithmic regression was performed. P less
han .05 was considered statistically signiﬁcant.
ESULTS
Figure 1A shows representative dot plots of ﬂow
ytometry analysis of CD62L and CCR7 expression
n CD4 T cells in a healthy individual (left), and two
ypes of abnormal patterns that we observed in pa-
ients with cGVHD (middle and right). The vertical
ine in the graph is set at the upper end of isotype
ntibody binding background, but the horizontal line
s set just below the CD62Lhigh population seen in
ealthy individuals. Note that even in healthy individ-
Involvement Sites
Immunosuppressive
Treatment at
Enrollment
kin, mouth musculoskeletal Pred/CSA
kin, mouth, lung eyes, musculoskeletal Pred/FK506
kin, mouth, lung eyes, musculoskeletal Pred
kin, mouth, liver musculoskeletal Pred/FK506
kin, lung Pred/FK506/MMF
kin, mouth, musculoskeletal Pred/FK506
kin, mouth, eyes musculoskeletal Pred/FK506
D, chronic graft-versus-host disease; CML, chronic myelogenous
male; FK506, tacrolimus; HD, Hodgkin’s disease; M, male; MMF,
isone; SCT, stem cell transplantation.T
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Bant that cannot be classiﬁed by the standard deﬁni-
ion as either central memory or effector memory
ells. These may represent cells in transition or some
ther unique population. The majority of patients
about two thirds) with cGVHD have a pattern closer
o that seen in the middle panel. We empirically tested
everal mathematic transformations of the data to see
hich transformation appeared to provide the greatest
istinction between a large sampling of healthy indi-
iduals and the symptomatic cGVHD group of pa-
ients. This transformation consisted of the ratio of
he percent of cells in the upper right quadrant (cen-
ral memory CD4 T cells) divided by the percent of
ells in the lower left quadrant (effector memory CD4
cells). This ratio is plotted for the entire group of 52
ealthy control blood samples, for 21 patients postal-
ogeneic transplantation without cGVHD, and for 37
atients with symptomatic cGVHD postallogeneic
igure 1. A, Flow cytometry dot plot analyses of peripheral blood
hromoﬂor) on vertical axis and CCR7 (CyChrome chromoﬂor) on
nd right panels, Patterns seen in two patients with cGVHD with
ypical of majority where loss of expression of CCR7 is more profo
as set just above staining by isotype CyChrome control antibody,
onors with high expression of CD62L. Numbers in each quadrant
vertical logarithmic scale) of mathematic transformation of data fro
atio of CCR7CD62Lhigh/CCR7CD62Llow CD4 T cells (perce
ealthy individuals (solid square, healthy), 21 patients postallogen
ostallogeneic transplantation with symptomatic cGVHD (solid cirransplantation in Figure 1B. v
B&MTHealthy individuals had an average ratio of 3.2 
.37 indicating a preponderance of central memory and
aive CD4 T cells. Patients postallogeneic transplan-
ation without cGVHD had similar average ratios
2.8  0.69, not signiﬁcantly different from control
ubjects). Patients with symptomatic cGVHD had
ower average ratios (0.78  0.11; P  .0001 com-
ared with normal, P  .0002 compared with the
on-cGVHD posttransplantation group). It is of note
hat the lowest ratio value for any healthy individual
as 0.72 and for any patient postallogeneic transplan-
ation without cGVHD was 0.73, whereas 23 of the 37
atients with cGVHD (62%) had a ratio below 0.72.
e have previously reported that corticosteroid ad-
inistration does not appear to affect numbers of
entral memory CD4 T cells [14]. When we applied
he above mathematic transformation (ratio of central
emory to effector memory CD4 cells) to these pre-
T cells assessing surface expression of CD62L (allophycocyanin
ntal axis. Left, Typical pattern seen in healthy individuals. Middle
e change noted in about 10% (right) and more moderate change
an loss of CD62L expression (middle). Vertical line in each graph
as horizontal line was set just below population of cells in healthy
e percent of events (cells) falling into that quadrant. B, Scatter plot
cytometry generated dot plots identical to those shown in A, where
per right quadrant divided by percent in lower left quadrant) in 52
nsplantation without cGVHD (‘, no GVHD), and 37 patients
VHD). Each dot represents one patient.CD4
horizo
extrem
und th
where
indicat
m ﬂow
nt in up
eic traiously published data from patients with autoimmune
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2isease on high-dose steroids the values were not
igniﬁcantly different from the normal range (2.5 
.50). This conﬁrms that chronic steroid administra-
ion is not likely a primary cause of the abnormal ratio
escribed for patients with symptomatic cGVHD.
owever, patients with cGVHD in general were also
n other immunosuppressives (most commonly ta-
rolimus), which could also inﬂuence these ratios.
In data not shown, we re-analyzed blood samples
rom some healthy individuals and patients to assess
he same mathematic ratio when the dot plot analysis
as restricted to only the memory (CD45RO CD4
-cell) populations (i.e., not including naive T cells).
e found the ratio for 25 healthy individuals to be
.2  0.37, for 12 patients postallogeneic transplan-
ation without cGVHD to be 1.6  0.38, and for 31
atients with cGVHD to be 0.59  0.07. The lowest
atio for a healthy individual was 0.48, where one of 12
atients posttransplantation without GVHD was be-
ow that (at 0.42), but 16 of 31 (52%) were below 0.48.
hus, the general conclusions regarding the ratio cal-
ulations apply even when the analysis was restricted
o the memory populations (statistical differences at
 .0001 for healthy compared with cGVHD; and
 .0002 for no cGVHD posttransplantation versus
GVHD). However, restriction to the memory pop-
lations did not appear to increase the speciﬁcity of
he analysis to distinguish the cGVHD population
rom the other groups. Because a 3-color analysis by
ow cytometry is signiﬁcantly easier to perform than
4-color analysis, we ignored the RA or RO status of
he CD4 T cells in the subsequent analyses that we
how below.
igure 2. Scatter plot showing data from ﬂow cytometry analysis of
ubtypes of peripheral blood CD8 T cells. Each ﬁlled symbol
epresents value for analysis of healthy individual whereas each open
ymbol represents value for analysis of patient with symptomatic
GVHD. Indicated are comparisons of populations of CD8T cells
hat are deﬁned as naive (CD45RACCR7), effector memory
Tem  CD45RACCR7), RA effector memory (Temra 
D45RACCR7) and central memory (Tcm  CD45RACR7). Each dot represents one patient.
6We next analyzed the CD8 T-cell populations
ith respect to expression of CD45RA and CCR7 to
numerate the following populations: naive (CD45RA
CR7), central memory (CD45RACCR7), effector
emory (CD45RACCR7), and RA effector mem-
ry (CD45RACCR7). The results of this analysis for
6 healthy individuals and 23 patients with cGVHD are
hown in Figure 2. Of note is that the CD8 T-cell
entral memory population stands out with regard to
igniﬁcance of the difference (P  .0001) between the
ealthy individuals (11.8  1.0%) and the patients with
GVHD (23.3  2.0%). Speciﬁcally, there is a signiﬁ-
ant increase in peripheral blood CD8 central memory
cells in patients with symptomatic cGVHD. This is in
ontrast to the CD4 T-cell analysis noted above where
here appears to be a loss of central memory cells in these
atients. We also see a trend (P .05) toward a decrease
n the RA effector memory cell population in the
GVHD group (25.9  2.7%) relative to healthy indi-
iduals (33.6  2.5%). We note that similar changes in
hese CD8 T-cell populations have been reported for
atients with rheumatoid arthritis, although not seen in
comparision group of patients in that study who had
ystemic lupus erythematosis [15]. The level of CCR4
xpression in central effector memory CD8 T cells
ay further distinguish between cytotoxic effector pre-
ursors (CCR4) and Tc2 cells (CCR4) [16]. There-
ore, we examined CCR4 expression speciﬁcally by
D8 central memory (CD45RACCR7) cells. There
as no statistical difference in the percent of CD8
entral memory T cells that expressed CCR4 relative to
hose that did not express CCR4 in healthy individuals (n
14, 39.6  4.7% of all central memory cells that
xpress CCR4) versus patients with cGVHD (n  19,
8.7  4.6%, P  .90) (data plots not shown).
In light of the contrasting changes in CD4 and
D8 cells, we combined the data in one plot as
hown in Figure 3 where the ratio of CD4 T cells
hat are CCR7CD62Lhigh/CCR7CD62Llow is
lotted on the vertical axis and the percent of CD8
D45RACCR7 (central memory) is plotted on
he horizontal axis. The group of 20 healthy indi-
iduals that were so analyzed cluster at the upper
eft side of the graph whereas 20 patients with
GVHD plotted in this way are distributed across
he lower part of the graph with a trend toward
ower right side of the graph. The 20 patients and
0 control subjects having both CD4 and CD8
nalysis represent a nonselected group representing
ll control subjects and patients studied after the
oint in time when we began to study not only the
D4, but also the CD8 populations. These plots
emonstrate that when both CD4 and CD8 popu-
ations are taken into account, there is a signiﬁcant
eparation of most of the cGVHD group from the
ontrol group, but there is some overlap.Seven patients with cGVHDwere treated with ECP
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Bs indicated earlier. All 7 patients demonstrated a re-
ponse to ECP in that performance criteria stabilized or
mproved while corticosteroid dosage was decreased by
t least 30% during the period of treatment (ECP treat-
ents occurred twice weekly for 3 months and then
wice every other week for the second 3 months). T-
ymphocyte subset analysis was performed before the
tart of ECP and at the end of the 6-month period of
CP treatments. Shown in Figure 4A is the paired pre-
nd post-ECP analysis of the ratio of CD4 central mem-
ry to effector memory cells (same measurements as in
igure 1B, but plotted as paired bar graphs). In 6 of 7
atients there was a normalization (increase) in this ratio
igure 3. Plots combine data for peripheral blood CD4 and CD8
B (vertical axis) and Figure 2 (horizontal axis) for subset of healthy d
ets of data are available. Regular symmetric ellipse was drawn and p
ver data similarly plotted for patients with cGVHD. Lines were pro
n each graph.
igure 4. Paired measurements of ratio of CCR7CD62Lhigh/CCR
ercent in lower left quadrant) (A) and percent of CD8 CD45ROB) from each of 7 patients before (blue) and after 6 months of ECP treat
B&MTn the post-ECP sample relative to the pre-ECP and this
hange was statistically signiﬁcant (P .046). When the
ercent of CD8 T cells that were central memory cells
ere plotted in Figure 4B there was a decrease toward
ormal values in 5 of the 7 patients and in many cases
his decrease was quite large. However, this trend for the
D8 central memory cell values did not reach statistical
igniﬁcance for the group of 7 as a whole.
ISCUSSION
In this study, we demonstrate that there is a highly
igniﬁcant increase in central memory CD8 T cells
subpopulations, respectively, as shown from scatter plots in Figure
(left) and patients with symptomatic cGVHD (right) for which both
o tightly include all values for healthy donors and then reproduced
by best-ﬁt algorithm of regression analysis as indicated in formulae
62Llow CD4 T cells (percent in upper right quadrant divided by
hat are also CCR7 (i.e., percent of central memory CD8 T cells)T-cell
onors
laced t
duced7CD
T-cell tments (red).
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2ogether with a highly signiﬁcant decrease in central
emory CD4 T cells associated with cGVHD. Fur-
hermore, we show that this abnormality of the bal-
nce of central and effector memory cells in cGVHD
as progressively normalized after ECP treatment in
ssociation with improvement of clinical symptoms.
ecause of the small number of patients studied with
CP it is not possible to say whether the clinical
mprovement achieved with ECP is a result of nor-
alization of central and effector memory cell ratios,
or can we determine yet whether such laboratory
hanges are predictive of clinical response. The pur-
ose of the current pilot study was to search for
bnormalities of T-lymphocytes that appear to nor-
alize after ECP treatment for cGVHD to identify
andidate blood cell markers that should be examined
n a larger series of patients undergoing ECP or other
ypes of treatments for cGVHD. In all 7 patients
articipating in the program of ECP treatments there
as clear evidence of a trend toward normalization of
he central/effector memory cell patterns in both CD4
nd CD8 cells, and this trend was statistically signiﬁ-
ant for the group of 7 as a whole for at least the CD4
entral memory to effector memory ratio.
Alloreactive donor-derived T cells are believed to
lay an important role in the pathogenesis of cGVHD;
owever, consistent statistically signiﬁcant patterns of
hanges in T cells associated with cGVHD have been
ifﬁcult to deﬁne. Many clinical manifestations of
GVHD overlap with features of autoimmune disor-
ers, thus, there may be similar patterns of changes in
ymphocyte phenotypes in these conditions. Notably,
n increase in central memory CD8 T cells has been
eported in patients with rheumatoid arthritis, but not
atients with systemic lupus erythematosus [15].
CD8 central memory T cells have been reported
o be heterogenous with respect to expression of
CR4, which may discriminate cells that are destined
o be committed to the TC2 pathway (CCR4) versus
cytotoxic TC1 pathway (CCR4) [16]. Although
e documented an increase in the central memory
D8 T-cell group as a whole, when we further
elineated the percentage of these that were CCR4
ersus those that were CCD4, we did not see a
ifference between patients with cGVHD and healthy
onors. We were interested in assessing this because
owler and Gress [17] have reported that allospeciﬁc
onor Tc2 cells reduce GVHD in murine transplanta-
ion models.
Despite this complexity it is possible to differen-
iate central and effector memory T-cell roles in im-
une function. For example, when stimulated in vitro
y T-cell receptors, central memory T cells produce
redominantly interleukin (IL)-2, whereas effector
emory T cells produce reduced levels of IL-2, but
igniﬁcant amounts of interferon- and IL-12 (TH1/
C1) or IL-4, IL-5, and IL-10 (TH2/TC2) [11]. C
8here is controversy regarding the differentiation
athway of these cells, including speciﬁc precursor/
rogeny relationship among naive, central memory,
nd effector memory T cells [18,19]. Furthermore,
here are likely differences between CD4 and the
D8 T-cell populations in this regard. Lanzavecchia
nd Sallusto [20] proposed a lineage model (applied
rimarily to CD4 cells) and suggested that naive T
ells differentiate ﬁrst into central memory, and then
nto effector memory cells. Wherry et al. [21] have
roposed an alternative pathway whereby naive CD8
cells differentiate into effector cells, then effector
emory cells, and ﬁnally into central memory cells.
aron et al. [22] have proposed that CD8 central and
ffector memory cells are independent subpopulations
hat do not interchange.
To our knowledge, this is the ﬁrst report that
emonstrates that cGVHD is associated with an im-
alance of central and effector memory cells that oc-
urs in both the CD4 and CD8 T-cell populations.
urthermore, our initial ﬁndings suggest that ECP is
ssociated with normalization of T-cell population
attern over time. The decrease in CD4 central
emory cells and increase in CD8 central memory
ells associated with cGVHD suggests different roles
layed by CD4 and CD8 central memory cells in
esponse to the intensive and unremitting alloimmune
ntigenic challenge that can occur in the setting of
ransplantation. Alternatively it is possible that differ-
nces in differentiation pathways for the two types of
cells may explain the contrasting abnormal patterns
f CD4 versus CD8 T cells in GVHD. As noted
bove there are a variety of models proposed for dif-
erentiation pathways.
Recently, Seder and Ahmed [18] proposed a model
or CD4 T cells that is slightly different for cells
estined for a TH1 type response versus those des-
ined for a TH2 type response. The model proposes
hat some naive CD4 T cells differentiate either
irectly into central memory cells or into effector
ells, and that central memory cells then give rise to
ffector memory cells. For the TH1 group, it is pro-
osed that effector cells producing interferon- and
elated cytokines are end-stage cells progressing to
poptosis, whereas for TH2 cells the effector cells
roducing IL-4 and related cytokines may progress to
ither central memory or effector memory cells. In
ny case the predominant pathway for CD4T cells is
aive to central memory to effector memory and then
ossibly to effector cells and ﬁnally to apoptosis. Seder
nd Ahmed [18] propose that for CD8 T cells the
athway appears to be a direct conversion of naive to
A effector to effect memory to central memory and
hen possibly to effector cells and apoptosis.
In attempting to ﬁt our observations to these mod-
ls of the differentiation pathways for CD4 and
D8 T cells, we propose in a schematic outline what
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Abnormal Central/Effector Memory T Cell Ratios
Bay be occurring in cGVHD (Figure 5). In healthy
ndividuals there is continuous age-appropriate gen-
ration of naive CD4 and CD8 T cells. In the case
f CD4 T cells the naive cells initially progress to a
entral memory phenotype that accumulates as the
redominant population. By contrast the normal dif-
erentiation pathway for CD8 T cells leads from
aive cells to RA effector memory or to effector
emory cells that accumulate as the predominant
opulation. It is known that allogeneic stem cell trans-
lantation and cGVHD adversely affect thymic func-
ion likely limiting the rate of generation of naive T
ells [23]. This would reduce the size of both CD4
nd CD8 naive cells. Added to this effect strong
llogeneic antigen stimulation would likely drive cells
hrough the pathway further reducing the size of the
D4 central memory population and the CD8 ef-
ector memory populations while slightly increasing
he CD4 effector memory and CD8 central mem-
ry populations. ECP might reverse this process by a
umber of mechanisms. Induction of apoptosis, par-
icularly that of dendritic antigen-presenting cells,
ay trigger tolerance perhaps by increasing the num-
ers of lymphocytes that acquire regulatory function.
urthermore, the reduction in response to antigenic
timulation might both reduce ongoing thymic dam-
ge/dysfunction and reduce the antigen-stimulated
rogression of lymphocyte differentiation. Thus, we
ropose that changes in the balance of central memory
nd effector memory cells occur as a consequence of
hymic dysfunction and unremitting antigen stimula-
ion associated with cGVHD. Similarly, normaliza-
ion of the balance of central memory and effector
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igure 5. Proposed scheme indicating differentiation pathways for
GVHD after response to ECP treatment. Arrows from left to righ
f that population. Naive, effector memory (Tem), RA effector memory cells associated with ECP is proposed to be a
B&MTonsequence of the induction of tolerance by mecha-
isms yet to be deﬁned. Larger prospective studies are
arranted to determine if the measurements we have
eﬁned are useful prognostic indicators and/or could
e used as a measure of and to guide response to
herapies.
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